Drs. Powles, Koshkin on the Q-TWiST Analysis for JAVELIN Bladder 100

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Centre at St. Bartholomew’s Hospital, and Vadim Koshkin, MD, University of California, San Francisco, break down the quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis conducted on the JAVELIN Bladder 100 study for the estimated net benefit of avelumab plus best supportive care versus best supportive care alone for patients with advanced urothelial carcinoma.

View more ASCO 2023 videos.